Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven I Sherman

Showing results (81-90 of 160) with videos related to

Pageof 16
Sort By:
Head & Neck|November 4, 2009
Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapyAarti Bhatia, Archana Rao, Kie-Kian Ang, et al.
The Journal of Clinical Endocrinology and Metabolism|July 23, 2018
Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive IodineTania Jaber, Steven G Waguespack, Maria E Cabanillas, et al.
Endocrine|February 4, 2017
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomesRobert I Haddad, Martin Schlumberger, Lori J Wirth, et al.
International Journal of Radiation Oncology, Biology, Physics|December 20, 2008
Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatmentDavid L Schwartz, Mark J Lobo, K Kian Ang, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2016
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid CancerBruce Robinson, Martin Schlumberger, Lori J Wirth, et al.
Thyroid : Official Journal of the American Thyroid Association|December 4, 2024
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid CarcinomaSarah Hamidi, Sireesha Yedururi, Mimi I Hu, et al.
The Oncologist|April 16, 2014
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancerRamona Dadu, Steven G Waguespack, Steven I Sherman, et al.
Cancer|August 16, 2016
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancerSteven I Sherman, Douglas O Clary, Rossella Elisei, et al.
Thyroid : Official Journal of the American Thyroid Association|January 20, 2006
Management guidelines for patients with thyroid nodules and differentiated thyroid cancerDavid S Cooper, Gerard M Doherty, Bryan R Haugen, et al.
The Journal of Clinical Endocrinology and Metabolism|October 30, 2014
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experienceRamona Dadu, Komal Shah, Naifa L Busaidy, et al.
Pageof 16

Showing results (81-90 of 160) with videos related to

Sort By:
Pageof 16
Head & Neck|November 4, 2009
Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapyAarti Bhatia, Archana Rao, Kie-Kian Ang, et al.
The Journal of Clinical Endocrinology and Metabolism|July 23, 2018
Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive IodineTania Jaber, Steven G Waguespack, Maria E Cabanillas, et al.
Endocrine|February 4, 2017
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomesRobert I Haddad, Martin Schlumberger, Lori J Wirth, et al.
International Journal of Radiation Oncology, Biology, Physics|December 20, 2008
Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatmentDavid L Schwartz, Mark J Lobo, K Kian Ang, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2016
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid CancerBruce Robinson, Martin Schlumberger, Lori J Wirth, et al.
Thyroid : Official Journal of the American Thyroid Association|December 4, 2024
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid CarcinomaSarah Hamidi, Sireesha Yedururi, Mimi I Hu, et al.
The Oncologist|April 16, 2014
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancerRamona Dadu, Steven G Waguespack, Steven I Sherman, et al.
Cancer|August 16, 2016
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancerSteven I Sherman, Douglas O Clary, Rossella Elisei, et al.
Thyroid : Official Journal of the American Thyroid Association|January 20, 2006
Management guidelines for patients with thyroid nodules and differentiated thyroid cancerDavid S Cooper, Gerard M Doherty, Bryan R Haugen, et al.
The Journal of Clinical Endocrinology and Metabolism|October 30, 2014
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experienceRamona Dadu, Komal Shah, Naifa L Busaidy, et al.
Pageof 16